Follitropin alfa biosimilar - Theramex
Alternative Names: OVALEAP; Ovaleap; XM 17Latest Information Update: 04 Nov 2021
At a glance
- Originator Ratiopharm
- Developer Theramex
- Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
- Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Female infertility
Most Recent Events
- 09 Mar 2021 Registered for Female infertility in Australia (SC)
- 31 Jan 2020 Preregistration for Female infertility in Australia (SC)
- 01 Feb 2018 Teva Women's Health was sold by Teva Pharmaceuticals to CVC Capital Partners, to create an international pharmaceutical company dedicated to Women’s Health named Theramex